Tribute Pharmaceuticals Canada (SLRXF) Inactive 10-K2014 FY Annual report

Filed: 3 Mar 15, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Bad

New words: abiding, abrupt, abusable, ACE, acetylsalicylic, agonist, alcohol, allegedly, analgesic, Anaprox, angina, anginal, angiotensin, antagonize, antianginal, antihypertensive, anxiolytic, arm, ASA, asserting, assertion, attainment, attendance, attorney, back, beta, bicarbonate, bilastine, bisoprolol, Blocadren, blockade, borne, bradycardia, Bystolic, calcium, candor, carvedilol, catecholamine, central, channel, CHEP, chloride, Circuit, circumvent, circumvented, circumventing, codeine, comparted, compatible, complimentary, concurrently, conjunctival, Consent, construction, consumption, core, Coreg, crime, cultural, cycle, de, deal, depreciation, depression, diastolic, dietary, dispute, disputing, diuretic, Dundee, duty, dysglycemia, dyslipidemia, ejection, EMA, emotional, encountered, ENDO, episodic, exacerbation, excretion, exponentially, expropriation, faith, Farma, fatigue, fibre, FMR, formula, Frisch, hand, handed, hard, hardware, healthy, hereof, hinder, hydrochlorothiazide, hypertension, idiopathic, inconsistent, Indenture, Inderal, induced, inexperienced, infeasible, inhibition, inside, intake, inventor, JD, Jumpstart, Kohl, labetalol, language, left, length, lifestyle, lifetime, Lopressor, Mackie, Marty, metoprolol, mg, mgs, Monocor, monotherapy, multiple, MycoVaTM, Naprosyn, nationalization, nebivolol, neck, nonfinancial, Notwithstanding, opposition, OTCQX, Outlook, output, overuse, Oxley, oxygen, paediatric, Paladin, Percocet, peripheral, pharmacotherapy, pindolol, plc, polytherapy, preclude, propranolol, randomly, rebound, redesign, redistribution, Reform, relaxant, renin, reproduce, resistance, resistant, retrospectively, reveal, run, SA, scalp, shopping, signature, Similarly, software, St, steady, stimulant, stolen, stringent, supersede, Supreme, survive, susceptible, sympathomimetic, syndicate, Syntex, systolic, tachycardia, tension, terrorist, therefrom, thiazide, tightening, timolol, tobacco, Toradol, tract, Trandate, transformational, true, Trust, TRX, TSX, unapproved, Underwriting, undue, unenforceability, unhealthy, unmarketed, unopposed, unrealized, UPM, urticaria, vagal, vasomotor, velocity, ventricular, Venture, viii, Viskazide, Visken, viv, XBRL

Removed: Amending, Australian, borrowing, Chinese, consisting, controlling, create, deem, direction, discounted, expansion, explained, fell, Glossary, Harmonization, Japanese, Phase, proxy, pursue, renewed, settled, sufficiency, trademarked, transitional, Uropol, USA, Watson, wholly, write

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

SLRXF similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Tribute Pharmaceuticals Canada Inc. (the “Company”) on Form 10-K for the year ended December 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Scott Langille, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and,

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 3, 2015


	/s/ Scott Langille
	Scott Langille
	Chief Financial Officer
	(principal financial officer)